{
    "root": "2acc6d84-e627-4384-9359-e7e20a55b6b6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "FANAPT",
    "value": "20250512",
    "ingredients": [
        {
            "name": "ILOPERIDONE",
            "code": "VPO7KJ050N"
        }
    ],
    "indications": "FANAPT® is indicated for: \n                  \n                     Treatment of schizophrenia in adults [see Clinical Studies (14.1)].\n                     \n                     Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2)].",
    "contraindications": "Administer FANAPT orally twice daily without regard to meals. ( 2.1 ) Titrate the dosage of FANAPT to avoid orthostatic hypotension. See Full Prescribing Information for titration schedule. ( 2.1 ) Recommended Dosage: Indication Starting Dosage Recommended Dosage Schizophrenia ( 2.1 ) 1 mg twice daily 6 mg to 12 mg twice daily Bipolar Mania ( 2.1 ) 1 mg twice daily 12 mg twice daily CYP2D6 Poor Metabolizers: See Full Prescribing Information for titration schedule and recommended dosage. ( 2.2 )",
    "warningsAndPrecautions": "FANAPT tablets are white, round and identified with a logo “” debossed on one side and tablet strength “1”, “2”, “4”, “6”, “8”, “10”, or “12” debossed on the other side. Tablets are supplied in the following strengths and package configurations:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              Package Configuration\n                           \n                           \n                              Tablet Strength (mg)\n                           \n                           \n                              NDC Code\n                           \n                        \n                        \n                           Bottles of 60\n                           1 mg\n                           43068-101-02\n                        \n                        \n                           Bottles of 60\n                           2 mg\n                           43068-102-02\n                        \n                        \n                           Bottles of 60\n                           4 mg\n                           43068-104-02\n                        \n                        \n                           Bottles of 60\n                           6 mg\n                           43068-106-02\n                        \n                        \n                           Bottles of 60\n                           8 mg\n                           43068-108-02\n                        \n                        \n                           Bottles of 60\n                           10 mg\n                           43068-110-02\n                        \n                        \n                           Bottles of 60\n                           12 mg\n                           43068-112-02\n                        \n                        \n                           Titration Pack A\n                           2x1 mg, 2x2 mg, 2x4 mg, 2x6 mg(Total of 8 tablets)\n                           43068-113-04\n                        \n                        \n                           Titration Pack C\n                           4x1 mg, 2x2 mg, 2x6 mg(Total of 8 tablets)\n                           43068-114-03\n                        \n                     \n                  \n                  \n                     Storage\n                  \n                  Store FANAPT tablets at controlled room temperature, 25℃ (77℉); excursions permitted to 15° to 30 ℃ (59° to 86℉) [See USP Controlled Room Temperature]. Protect FANAPT tablets from exposure to light and moisture.",
    "adverseReactions": "FANAPT is contraindicated in individuals with a known hypersensitivity reaction to the product. Anaphylaxis, angioedema, and other hypersensitivity reactions have been reported [see Adverse Reactions (6.2)]."
}